Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.


Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
03 09 2021
Historique:
pubmed: 29 7 2021
medline: 18 1 2022
entrez: 28 7 2021
Statut: ppublish

Résumé

Ceftazidime-avibactam (CZA) has emerged as a promising solution to the lack of new antibiotics against Pseudomonas aeruginosa infections. Data from

Identifiants

pubmed: 34319141
doi: 10.1128/Spectrum.00585-21
pmc: PMC8552783
doi:

Substances chimiques

Anti-Bacterial Agents 0
Azabicyclo Compounds 0
Drug Combinations 0
avibactam, ceftazidime drug combination 0
Ceftazidime 9M416Z9QNR

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0058521

Références

Antimicrob Agents Chemother. 2018 Jun 26;62(7):
pubmed: 29760124
Antimicrob Agents Chemother. 2011 Jul;55(7):3284-94
pubmed: 21555763
J Glob Antimicrob Resist. 2020 Sep;22:18-27
pubmed: 31863899
Antimicrob Agents Chemother. 2009 Aug;53(8):3430-6
pubmed: 19433570
BMC Infect Dis. 2013 Aug 19;13:380
pubmed: 23957376
PLoS Comput Biol. 2011 Jan 06;7(1):e1001043
pubmed: 21253559
J Antimicrob Chemother. 2012 Jun;67(6):1354-8
pubmed: 22441578
Drug Resist Updat. 2015 Jul-Aug;21-22:41-59
pubmed: 26304792
J Glob Antimicrob Resist. 2019 Sep;18:37-44
pubmed: 31154007
CPT Pharmacometrics Syst Pharmacol. 2017 Mar;6(3):197-207
pubmed: 28145085
Antimicrob Agents Chemother. 2015 Oct;59(10):6605-7
pubmed: 26195508
Drug Resist Updat. 2011 Feb;14(1):1-21
pubmed: 21288762
Int J Antimicrob Agents. 2016 Dec;48(6):725-727
pubmed: 28128096
Int J Infect Dis. 2017 Dec;65:1-3
pubmed: 28951106
Antimicrob Agents Chemother. 2017 Jun 27;61(7):
pubmed: 28461318
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28827415
Infect Dis (Lond). 2020 Sep;52(9):616-624
pubmed: 32427010
Infection. 2009 Oct;37(5):461-5
pubmed: 19499183
Antimicrob Agents Chemother. 2015 Nov 16;60(2):752-6
pubmed: 26574008
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29530842
Clin Ther. 2001 Aug;23(8):1231-44
pubmed: 11558860
Int J Antimicrob Agents. 2019 May;53(5):612-619
pubmed: 30682497
Eur Rev Med Pharmacol Sci. 2013 Feb;17(3):285-91
pubmed: 23426530
J Antimicrob Chemother. 2018 Mar 1;73(3):658-663
pubmed: 29149337
Antimicrob Agents Chemother. 2003 Mar;47(3):905-9
pubmed: 12604520
Int J Antimicrob Agents. 2019 Aug;54(2):255-260
pubmed: 31071465
Ann Lab Med. 2017 Mar;37(2):174-176
pubmed: 28029009
Eur J Clin Pharmacol. 2020 Mar;76(3):349-361
pubmed: 31836928
Curr Infect Dis Rep. 2020 Jan 13;22(1):1
pubmed: 31933158
Infect Dis (Lond). 2017 Jul;49(7):521-527
pubmed: 28264618
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28993338
Antimicrob Agents Chemother. 2010 Jun;54(6):2646-54
pubmed: 20368395
Antimicrob Agents Chemother. 2015 May;59(5):2515-24
pubmed: 25691628
Diagn Microbiol Infect Dis. 2021 Jan;99(1):115227
pubmed: 33086177
Intensive Care Med. 2014 Jul;40(7):998-1005
pubmed: 24687298
Antimicrob Agents Chemother. 2015 Feb;59(2):1020-9
pubmed: 25451057
Antimicrob Agents Chemother. 2020 Mar 24;64(4):
pubmed: 32041712
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28223379
Antimicrob Agents Chemother. 2013 Oct;57(10):5104-11
pubmed: 23917322
J Antimicrob Chemother. 2018 Feb 1;73(2):456-461
pubmed: 29149302
Antimicrob Agents Chemother. 2017 Mar 24;61(4):
pubmed: 28167541
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28874376
Antimicrob Agents Chemother. 2019 Jul 25;63(8):
pubmed: 31182535

Auteurs

María M Montero (MM)

Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra Barcelona, Barcelona, Spain.

Sandra Domene Ochoa (S)

Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra Barcelona, Barcelona, Spain.

Carla López-Causapé (C)

Servicio de Microbiología y Unidad de Investigación, Hospital Son Espases, IdISBa, Palma de Mallorca, Spain.

Sonia Luque (S)

Pharmacy Service, Hospital del Mar, Barcelona, Spain.

Luisa Sorlí (L)

Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra Barcelona, Barcelona, Spain.

Núria Campillo (N)

Pharmacy Service, Hospital del Mar, Barcelona, Spain.

Inmaculada López Montesinos (I)

Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra Barcelona, Barcelona, Spain.

Eduardo Padilla (E)

Laboratori de Referència de Catalunya, Barcelona, Spain.

Núria Prim (N)

Laboratori de Referència de Catalunya, Barcelona, Spain.

Ariadna Angulo-Brunet (A)

Psychology and Education Science Studies, Universitat Oberta de Catalunya, Barcelona, Spain.

Santiago Grau (S)

Pharmacy Service, Hospital del Mar, Barcelona, Spain.

Antonio Oliver (A)

Servicio de Microbiología y Unidad de Investigación, Hospital Son Espases, IdISBa, Palma de Mallorca, Spain.

Juan P Horcajada (JP)

Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH